文献

J-GLOBAL ID：201702244793870657   整理番号：17A0386308

過去の化学療法レジメン数に応じた再発卵巣癌のゲムシタビンに対する反応性と毒性

Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens

著者 (10件)： Takei Yuji (Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan) ,  Takahashi Yoshifumi (Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan) ,  Machida Shizuo (Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan) ,  Taneichi Akiyo (Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan) ,  Takahashi Suzuyo (Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan) ,  Nagashima Tomomi (Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan) ,  Morisawa Hiroyuki (Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan) ,  Saga Yasushi (Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan) ,  Matsubara Shigeki (Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan) ,  Fujiwara Hiroyuki (Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan)
資料名： Journal of Obstetrics and Gynaecology Research  (Journal of Obstetrics and Gynaecology Research)
巻： 43  号： 2  ページ： 358-364  発行年： 2017年02月 
JST資料番号： W1429A  ISSN： 1341-8076  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： 目的:ゲムシタビンは,タキサン/プラチナ耐性再発卵巣癌に対す...

シソーラス用語： 薬物療法 ,...
準シソーラス用語： *再発卵巣腫瘍

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0386308&from=J-GLOBAL&jstjournalNo=W1429A") }}

著者キーワード (5件)： gemcitabine ,  ovarian cancer ,  previous chemotherapy regimen ,  response ,  toxicity

分類 (3件)： 女性生殖器と胎児の腫よう  (GS04000K) ,  腫ようの薬物療法  (GE03032C) ,  抗腫よう薬の臨床への応用  (GW16020L)

物質索引 (1件)： ゲムシタビン

引用文献 (22件)：

• Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95: S161-S192.
• Mutch DG, Orlando M, Goss T et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25: 2811-2818.
• Fernandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008; 26: 890-896.
• ten Bokkel HW, Lane SR, Ross GA. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004; 15: 100-103.
• Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: A randomized phase M study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19: 3312-3322.

タイトルに関連する用語 (6件)： 化学療法 ,  レジメン ,  再発卵巣癌 ,  ゲムシタビン ,  反応性 ,  毒性